| 引用本文: | 刘贤忠,徐志波,张先元,张丽婷,童卫泉,王帅,王璐,陈芳.贝伐单抗联合铂类治疗晚期非小细胞肺癌疗效与安全性的Meta分析[J].中国现代应用药学,2015,32(11):1382-1388. |
| LIU Xianzhong,XU Zhibo,ZHU Xianyuan,ZHANG Liting,TONG Weiquan,WANG Shuai,WANG Lu,CHEN Fang.Meta-analysis of Efficacy and Security of Bevacizumab Combined with Platinum in the Treatment of Advanced Non-small-cell Lung Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(11):1382-1388. |
|
| 摘要: |
| 目的 评估贝伐单抗联合铂类治疗晚期非小细胞肺癌(non-small-cell lung cancer，NSCLC)的疗效性和安全性。方法 检索Pubmed、Elsevier sciencedirect、CENTRAL、CNKI、CBM、万方、维普等国内外重要文献数据库，使用Review Manager 5.2软件对贝伐单抗治疗晚期NSCLC的总缓解率、无疾病进展期、总生存期、不良反应、死亡率进行Meta分析。结果 共纳入7篇文献，Meta分析表明：①高、低剂量贝伐单抗能显著提高铂类化疗治疗晚期NSCLC总缓解率(P<0.000 01)，显著延长无疾病进展期(P<0.000 01)；②高剂量贝伐单抗能显著延长铂类化疗治疗晚期NSCLC总生存期(P<0.000 01)，低剂量则不能改善总生存期；③高、低剂量贝伐单抗均会增加铂类化疗治疗晚期NSCLC的不良反应发生率(P<0.05)，且均不能降低死亡风险。结论 贝伐单抗联合铂类化疗能明显改善晚期NSCLC的总缓解率、无疾病进展期及总生存期，但同时会增加不良反应的发生，且不能降低死亡率。 |
| 关键词: 贝伐单抗 非小细胞肺癌 铂类 化疗 Meta分析 肿瘤 |
| DOI： |
| 分类号: |
| 基金项目:国家自然科学基金青年项目(81302934)；浙江省科技厅钱江人才计划(2012R10063)；浙江省卫生厅医药卫生科技计划项目(2013KYA140) |
|
| Meta-analysis of Efficacy and Security of Bevacizumab Combined with Platinum in the Treatment of Advanced Non-small-cell Lung Cancer |
|
LIU Xianzhong1, XU Zhibo2, ZHU Xianyuan3, ZHANG Liting1, TONG Weiquan1, WANG Shuai1, WANG Lu1, CHEN Fang4
|
|
1.The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China;2.The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, China;3.Emergency Department, Hnagzhou Hospital of Traditional Chinese Medicine, Hangzhou 310007, China;4.Pulmonary Function Test Room, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China
|
| Abstract: |
| OBJECTIVE To evaluate the efficacy and security of bevacizumab combined with platinum in the treatment of advanced non-small-cell lung cancer(NSCLC). METHODS Clinical literature of bevacizumab and platinum in treating NSCLC were collected from Pubmed, Elsevier sciencedirect, CENTRAL, CNKI, CBM, Wangfang and VIP etc. Review Manager 5.2 was used for Meta-analysis of overall remission, progression free survival, overall survival, adverse effects and death rate of advanced NSCLC treated with bevacizumab. RESULTS Seven papers were included. The Meta-anaylysis results suggested that ①high and low dose bevacizumab obviously improved overall remission rate and progression free survival of advanced NSCLC patients(P<0.000 01); ②high dose bevacizumab obviously prolonged overall survival of NSCLC patients(P<0.000 01), but low dose bevacizumab had no significant effect on ooverall survival; ③high and low dose bevacizumab could increase incidence of adverse effect without effect of motality. CONCLUSION Bevacizumab combined with platinum can obviously improve overall remission, progression free survival and overall survival of NSCLC patients, but it also increases incidence of adverse effects and can’t reduce motality. |
| Key words: bevacizumab non-small-cell lung cancer platinum chemotherapy Meta-analysis tumor |
